577 related articles for article (PubMed ID: 29143068)
1. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
[TBL] [Abstract][Full Text] [Related]
2. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
[TBL] [Abstract][Full Text] [Related]
3. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
4. Analysis of clinical characteristics of bone marrow proliferative tumor progression to acute myeloid leukemia.
Li Y; Zhang XY; Han J; Wang L
Cancer Biomark; 2018; 23(4):469-472. PubMed ID: 30452397
[TBL] [Abstract][Full Text] [Related]
5. [Clinical and epidemiological characteristics of the Philadelphia negative myeloproliferative neoplasms in Chile].
Valladares X; Benavente R; Rojas C; Peña C; Valenzuela R; Monardes V; López H; Abarca M; León P; Osorio R; Pérez E; Soto P; Rocca G; Cardemil D; Torres V; Intriago M; Cabrera ME; Undurraga MS
Rev Med Chil; 2021 Dec; 149(12):1687-1693. PubMed ID: 35735335
[TBL] [Abstract][Full Text] [Related]
6. [Clinical and epidemiological characteristics of the Philadelphia negative myeloproliferative neoplasms in Chile].
Valladares X; Benavente R; Rojas C; Peña C; Valenzuela R; Monardes V; López H; Abarca M; León P; Osorio R; Pérez E; Soto P; Rocca G; Cardemil D; Torres V; Intriago M; Cabrera ME; Undurraga MS
Rev Med Chil; 2021 Nov; 149(11):1532-1538. PubMed ID: 35735314
[TBL] [Abstract][Full Text] [Related]
7. Leukocytosis and MPNs: Where do we stand?
Coltoff A
Leuk Lymphoma; 2023 Mar; 64(3):564-572. PubMed ID: 36519233
[TBL] [Abstract][Full Text] [Related]
8. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.
Deadmond MA; Smith-Gagen JA
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2131-8. PubMed ID: 25968903
[TBL] [Abstract][Full Text] [Related]
9. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.
Landgren O; Goldin LR; Kristinsson SY; Helgadottir EA; Samuelsson J; Björkholm M
Blood; 2008 Sep; 112(6):2199-204. PubMed ID: 18451307
[TBL] [Abstract][Full Text] [Related]
10. Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea.
Lim Y; Lee JO; Bang SM
J Korean Med Sci; 2016 Oct; 31(10):1579-85. PubMed ID: 27550486
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.
Shallis RM; Zeidan AM; Wang R; Podoltsev NA
Hematol Oncol Clin North Am; 2021 Apr; 35(2):177-189. PubMed ID: 33641862
[TBL] [Abstract][Full Text] [Related]
12. Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients.
Geyer HL; Scherber RM; Dueck AC; Kiladjian JJ; Xiao Z; Slot S; Zweegman S; Sackmann F; Fuentes AK; Hernández-Maraver D; Döhner K; Harrison CN; Radia D; Muxi P; Besses C; Cervantes F; Johansson PL; Andreasson B; Rambaldi A; Barbui T; Vannucchi AM; Passamonti F; Samuelsson J; Birgegard G; Mesa RA
Blood; 2014 Jun; 123(24):3803-10. PubMed ID: 24553173
[TBL] [Abstract][Full Text] [Related]
13. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.
Mesa RA; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Naim A; Parasuraman S; Boyle J; Mascarenhas JO
Cancer; 2017 Feb; 123(3):449-458. PubMed ID: 27690182
[TBL] [Abstract][Full Text] [Related]
14. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors.
Cerquozzi S; Tefferi A
Blood Cancer J; 2015 Nov; 5(11):e366. PubMed ID: 26565403
[TBL] [Abstract][Full Text] [Related]
15. Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
Mesa R; Jamieson C; Bhatia R; Deininger MW; Gerds AT; Gojo I; Gotlib J; Gundabolu K; Hobbs G; Klisovic RB; Kropf P; Mohan SR; Oh S; Padron E; Podoltsev N; Pollyea DA; Rampal R; Rein LA; Scott B; Snyder DS; Stein BL; Verstovsek S; Wadleigh M; Wang ES; Bergman MA; Gregory KM; Sundar H
J Natl Compr Canc Netw; 2016 Dec; 14(12):1572-1611. PubMed ID: 27956542
[TBL] [Abstract][Full Text] [Related]
16. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.
Mesa R; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Boyle J; Mascarenhas JO
BMC Cancer; 2016 Feb; 16():167. PubMed ID: 26922064
[TBL] [Abstract][Full Text] [Related]
17. Flow cytometry immunophenotypic analysis of Philadelphia-negative myeloproliferative neoplasms: Correlation with histopathologic features.
Ouyang J; Zheng W; Shen Q; Goswami M; Jorgensen JL; Medeiros LJ; Wang SA
Cytometry B Clin Cytom; 2015; 88(4):236-43. PubMed ID: 25557358
[TBL] [Abstract][Full Text] [Related]
18. MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria.
Yassin MA; Taher A; Mathews V; Hou HA; Shamsi T; Tuğlular TF; Xiao Z; Kim SJ; Depei W; Li J; Rippin G; Sadek I; Siddiqui A; Wong RS
Cancer Med; 2020 Jul; 9(13):4512-4526. PubMed ID: 32351024
[TBL] [Abstract][Full Text] [Related]
19. [Clinical and genetic characteristics of young patients with myeloproliferative neoplasms].
Zhang MY; Bao M; Shi DY; Shi HX; Liu XL; Xu N; Duan MH; Zhuang JL; Du X; Qin L; Hui WH; Liang R; Wang MF; Chen Y; Li DY; Yang W; Tang GS; Zhang WH; Kuang X; Su W; Han YQ; Chen LM; Xu JH; Liu ZG; Huang J; Zhao CT; Tong HY; Hu JD; Chen CY; Chen XQ; Xiao ZJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2023 Mar; 44(3):193-201. PubMed ID: 37356980
[No Abstract] [Full Text] [Related]
20. Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Sankar K; Stein BL; Rampal RK
Cancer Treat Res; 2019; 179():159-178. PubMed ID: 31317487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
